Keywords
How to Cite
Abstract
During last years monoclonal antibodies (MAB) directed against vascular endothelium markers demonstrated their efficiency for visualization and targeted delivery of therapeutic drugs to tumors. Endoglin (CD105) which serves as a key element that determines endothelial cells quiescence or activation is one of such markers. Endoglin is highly expressed on the vascular endothelium of growing tumors. A first panel of MAB against endoglin in our country was produced at the hybridoma technology laboratory of RRC RST named after A.M. Granov. On the basis of these MAB ELISA was created allowing detection of endoglin in human plasma and other biological fluids. Several MAB had been shown to bind endoglin on the membrane of the cultured endothelial cells and to persist there for several hours. During the first 30 min after binding some of the immune complexes “endoglin-MAB” were internalized into the cytoplasm and were found included in the endosomes. In future these MAB can be used to create the reagents for the addressed delivery of isotope tags both on the membrane and into the cytoplasm of endothelial cells.References
Смирнов И.В., Грязева И.В., Самойлович М.П. и др. Панель моноклональных антител против эндоглина человека: получение и характеристика//Цитология. -2015. -Т. 57. -№ 7. -С. 499-508.
Смирнов И.В., Грязева И.В., Самойлович М.П., Климович В.Б. Эндоглин (CD105) -мишень визуализации и анти-ангиогенной терапии злокачественных опухолей//Вопросы онкологии. -2015. -Т. 61. -№ 6. -С. 898-907.
EINs L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity//Nat. Rev. Cancer. -2008. -Vol. 8. -№ 8. -P 579-591.
Hawinkels L.J., Kuiper P., Wiercinska e. et al. Matrix metal-loproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis//Cancer Res. -2010. -Vol. 70. -P 4141-4150.
Kerbel R.S. Tumor angiogenesis//n. Engl. J. Med. -2008. -Vol. 358. -P. 2039-2049.
Ollauri -Ib ez C., Lpez-Novoa J.M., Pericacho M. Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies//Expert Opin. Biol. Ther. -2017. -Vol. 17. -№ 9. -P. 1053-1063.
Paauwe M., ten Dijke P., Hawinkels L.J. Endoglin for tumor imaging and targeted cancer therapy//Expert Opin. Ther. Targets. -2013. -Vol. 4. -P. 421-435.
Pardali E., van der Schaff D.W., Wiercinska E. et al. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma//Oncogene. -2011. -Vol. 30. -P 334345.
Rosen L.S., Hurwitz H.I., Wong M.K. et al. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer//Clin. Cancer Res. -2012. -Vol. 18. -P 4820-4829.
Shiozaki K., Harada N., Greco W.R. et al. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin//Cancer Immunol. Immunother. -2006. -Vol. 55. -P. 140-150.
Smirnov I.V., Gryazeva I.V., Samoylovich M.P et al. Different pairs of monoclonal antibodies detect variable amounts of soluble endoglin in human blood plasma//Immunochem. Immunopathol. -2016. -Vol. 2. -P. 121.
Takahashi N., Haba A., Matsuno F., Seon B.K. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide//Cancer Res. -2001. -Vol. 61. -P. 7846-7854.
Thorpe P.E. Vascular targeting agents as cancer therapeutics//Clin. Cancer Res. -2004. -Vol. 15. -P 415427.
Welti J., Loges S., Dimmeler S., Carmeliet P Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer//J. Clin. Invest. -2013. -Vol. 123. -№ 8. -P. 3190-3200.
Zhang Y., Hong H., Orbay H. et al. PET imaging of CD105/endoglin expression with 61/64Cu-labeled Fab antibody fragment//Eur. J. Nucl. Med. Mol. Imaging. -2013. -Vol. 40. -P. 759-767.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018